机译:用可逆内皮脂肪酶抑制剂观察PK / PD断开连接
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
Research and Development Bristol-Myers Squibb Princeton;
coronary artery disease (CAD); Endothelial lipase (EL); high density lipoprotein (HDL); reverse cholesterol transport (RCT);
机译:用可逆内皮脂肪酶抑制剂观察PK / PD断开连接
机译:人口药代动力学(PK)和药代动力学药物动力学(PK / PD)对健康受试者的GDC-0334(TRPA1抑制剂)的评估。
机译:口服泛RAF激酶抑制剂MLN2480的临床药代动力学(PK),翻译PK /药效学(PD)和暴露-不良事件(AEs)关系
机译:CDK抑制剂PD 0332991选择性抑制肺腺癌细胞,而不会牺牲基质嵌入的内皮细胞对肿瘤增殖的能力调节作用
机译:Btk抑制剂的机理性PK / PD建模和用于细菌感染诊断的PET示踪剂的开发
机译:用可逆内皮细胞观察到PK / PD断开脂肪酶抑制剂
机译:鉴定证明体内HDLC增加的内皮脂肪酶(EL)的可逆小分子抑制剂